{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:29:31Z","timestamp":1781522971806,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jfma.2024.09.033","type":"journal-article","created":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T22:51:16Z","timestamp":1727823076000},"page":"794-799","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease"],"prefix":"10.1016","volume":"124","author":[{"given":"Cheng-Jui","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Jung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Jen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8585-4392","authenticated-orcid":false,"given":"Ming-Ju","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai-Szu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jfma.2024.09.033_bib1","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metabol"},{"issue":"6","key":"10.1016\/j.jfma.2024.09.033_bib2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.amjms.2020.07.011","article-title":"When and how to diagnose Fabry disease in clinical pratice","volume":"360","author":"Michaud","year":"2020","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.jfma.2024.09.033_bib3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1750-1172-5-14","article-title":"Expression of the disease on female carriers of X-linked lysosomal disorders: a brief review","volume":"5","author":"Pinto","year":"2010","journal-title":"Orphanet J Rare Dis"},{"issue":"4","key":"10.1016\/j.jfma.2024.09.033_bib4","first-page":"337","article-title":"TSOC expert consensus on the clinical features, diagnosis, and clinical management of cardiac manifestations of Fabry disease","volume":"37","author":"Hung","year":"2021","journal-title":"Acta Cardiol Sin"},{"issue":"2","key":"10.1016\/j.jfma.2024.09.033_bib5","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \"kidney disease: improving global outcomes\" (KDIGO) controversies conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.jfma.2024.09.033_bib6","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1159\/000494678","article-title":"Results of Fabry disease screening in male pre-end stage renal disease patients with unknown etiology found through the platform of a Chronic Kidney Disease Education Program in a Northern Taiwan Medical Center","volume":"43","author":"Lin","year":"2018","journal-title":"Kidney Blood Press Res"},{"issue":"7","key":"10.1016\/j.jfma.2024.09.033_bib7","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1002\/ejhf.1960","article-title":"An expert consensus document on the management of cardiovascular manifestations of Fabry disease","volume":"22","author":"Linhart","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jfma.2024.09.033_bib8","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2215\/CJN.08780812","article-title":"Screening of male dialysis patients for Fabry disease by plasma globotriaosylsphingosine","volume":"8","author":"Maruyama","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.jfma.2024.09.033_bib9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metabol"},{"key":"10.1016\/j.jfma.2024.09.033_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13023-015-0253-6","article-title":"Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document","volume":"10","author":"Biegstraaten","year":"2015","journal-title":"Orphanet J Rare Dis"},{"issue":"3","key":"10.1016\/j.jfma.2024.09.033_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s10545-017-0032-8","article-title":"Enzyme replacement therapy and beyond-in memoriam Roscoe O. Brady, M.D. (1923\u20132016)","volume":"40","author":"Ries","year":"2017","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"10.1016\/j.jfma.2024.09.033_bib12","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/ndt\/gfs526","article-title":"Fabry nephropathy: indications for screening and guidance for diagnosis and treatment by the European Renal Best Practice","volume":"28","author":"Terryn","year":"2013","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.jfma.2024.09.033_bib13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.kint.2016.10.004","article-title":"Screening, diagnosis, and management of patients with Fabry disease: conclusions from a \u201ckidney disease: improving global outcomes\u201d (KDIGO) controversies conference","volume":"91","author":"Schiffmann","year":"2017","journal-title":"Kidney Int"},{"issue":"913","key":"10.1016\/j.jfma.2024.09.033_bib14","first-page":"10","article-title":"FDA approves Galafold, a triumph for Amicus","volume":"36","author":"Moran","year":"2018","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.jfma.2024.09.033_bib15","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/1471-2369-15-72","article-title":"Fabry nephropathy: a review - how can we optimize the management of Fabry nephropathy?","volume":"15","author":"Waldek","year":"2014","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.jfma.2024.09.033_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110779","article-title":"Therapeutic advances in Fabry disease: the future awaits","volume":"131","author":"Kant","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.jfma.2024.09.033_bib17","first-page":"69","article-title":"Enzyme replacement therapy for Fabry disease: some answers but more questions","volume":"7","author":"Alfadhel","year":"2011","journal-title":"Therapeut Clin Risk Manag"},{"issue":"5","key":"10.1016\/j.jfma.2024.09.033_bib18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10157-018-01684-4","article-title":"Optimal follow-up intervals for different stages of chronic kidney disease: a prospective observational study","volume":"23","author":"Hirano","year":"2019","journal-title":"Clin Exp Nephrol"},{"issue":"1","key":"10.1016\/j.jfma.2024.09.033_bib19","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41436-020-00968-z","article-title":"Assessment of plasma lyso-Gb3 for clinical monitoring of treatment response in migalastat-treated patients with Fabry disease","volume":"23","author":"Bichet","year":"2021","journal-title":"Genet Med"},{"issue":"3","key":"10.1016\/j.jfma.2024.09.033_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2023.107603","article-title":"Global reach of over 20 years of experience in the patient-centered Fabry Registry: advancement of Fabry disease expertise and dissemination of real-world evidence to the Fabry community","volume":"139","author":"Wanner","year":"2023","journal-title":"Mol Genet Metabol"},{"issue":"9","key":"10.1016\/j.jfma.2024.09.033_bib21","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multi-organ system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"issue":"2","key":"10.1016\/j.jfma.2024.09.033_bib22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.beem.2014.10.003","article-title":"Fabry disease and the heart","volume":"29","author":"Seydelmann","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.jfma.2024.09.033_bib23","doi-asserted-by":"crossref","first-page":"694","DOI":"10.2215\/CJN.07680715","article-title":"Educating patients about CKD: the path to self-management and patient-centered care","volume":"11","author":"Narva","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.jfma.2024.09.033_bib24","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s13023-019-1254-7","article-title":"Treatment needs and expectations for Fabry disease in France: development of a new Patient Needs Questionnaire","volume":"14","author":"No\u00ebl","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.jfma.2024.09.033_bib25","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s13023-022-02417-3","article-title":"Burden associated with Fabry disease and its treatment in 12\u201315-year-olds: results from a European survey","volume":"17","author":"Bashorum","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"10.1016\/j.jfma.2024.09.033_bib26","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1007\/s10545-009-1254-1","article-title":"Psychological aspects of patients with Fabry disease","volume":"32","author":"Crosbie","year":"2009","journal-title":"J Inherit Metab Dis"},{"key":"10.1016\/j.jfma.2024.09.033_bib27","article-title":"Shared decision making between patients with Fabry disease and physicians in Japan: an online survey","volume":"32","author":"Inagaki","year":"2022","journal-title":"Mol Genet Metab Rep"},{"issue":"1","key":"10.1016\/j.jfma.2024.09.033_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s44162-023-00026-7","article-title":"Development of a validated risk assessment tool for Fabry disease utilizing electronic health record data","volume":"3","author":"Lobel","year":"2024","journal-title":"Journal of Rare Diseases"},{"key":"10.1016\/j.jfma.2024.09.033_bib29","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1186\/s13023-021-02150-3","article-title":"A new approach to identifying patients with elevated risk for Fabry disease using a machine learning algorithm","volume":"16","author":"Jefferies","year":"2021","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624004534?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664624004534?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:32:18Z","timestamp":1762331538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664624004534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0929664624004534"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2024.09.033","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Insights of Fabry disease: Expert consensus approach for screening, diagnosis, and multidisciplinary management in chronic kidney disease","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2024.09.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}